Seres Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Seres Therapeutics, Inc. (MCRB) had Available-for-sale Securities, Amortized Cost Basis of $75.10 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-09
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $75.10M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $114.04M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $125.37M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $141.71M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $75.10M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $114.04M 10-Q · filed 2018-05-09 |
| 2017-09-30 | $125.37M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $141.71M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $160.42M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $175.60M 10-K · filed 2018-03-08 |
| 2016-09-30 | $200.93M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $212.54M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $109.94M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $131.12M 10-K · filed 2017-03-16 |
| 2015-09-30 | $149.65M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $55.41M 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |